Therapy Areas: Cardiovascular
Arrow Named Chief Financial Officer at Strateos
13 February 2023 - - US-based life science research remote access laboratories and lab automation software provider Strateos, Inc has appointed Alexander K. Arrow, MD, CFA, as chief financial officer, the company said.

Dr. Arrow will join the executive leadership team and play a key role in leading the company's business and finance strategy focused on growth and new investments.

The company has also named Juliet M. Moritz, MPH, vice president, Project Management Office, reflecting the significant demand by large pharmaceutical companies and contract research organizations for deployment of Strateos Lodestar Software.

In this role, she will oversee all customer deployments used to streamline and optimize drug discovery, protein engineering, synthetic biology and antibody development processes.

Dr. Arrow is a medical technology executive with 27 years of experience in management and finance roles.

He comes to Strateos from commercial-stage medical technology manufacturer Carlsmed, Inc., where he was the chief financial officer.

In this role, he led the company's finance department with three equity rounds and two debt facilities.

Prior to Carlsmed, he was the CEO of Zelegent, Inc., which develops, manufactures, and sells minimally invasive tools for otolaryngologists.

He previously served as the president & COO of Biolase, Inc. (NASDAQ: BIOL), and the CFO of Arstasis, Inc., a cardiovascular device manufacturer.

Before his operating roles, Dr. Arrow spent nine years in equity research at three Wall Street firms, the last five years as the head of med tech research at Lazard, Ltd., and two years as the CFO of The Patent & License Exchange, a SaaS company funded by Softbank in 2000.

He holds a medical doctorate from Harvard Medical School and a bachelor's degree in biophysics, magna cum laude, from Cornell University.

Moritz, MPH, brings over thirty years of experience across various phases of drug development to Strateos.

She joins from Elligo Health Research, where she was executive vice president for Research Operations and was responsible for the management of more than half of the company's total employees and successfully oversaw the integration and reorganization of the project management and related services teams.

Prior to Elligo, she was senior vice president, Market Development for Premier Research, a global clinical research organization, focusing on the continued expansion of Premier's decentralized research offerings.

Prior to Premier, Moritz served as chief operating officer of Illingworth Research, a global contract specialist services provider that was acquired by Syneos Health in 2020.

She also held operational and quality assurance positions of increasing responsibility for biopharmaceutical companies that include Wyeth Pharmaceuticals, Pfizer, AstraZeneca, and Knopp Biosciences.

Moritz holds a BS in Biology from the University of Pennsylvania, a Masters of Public Health with honors from Drexel University and is pursuing a Doctorate in Bioethics from Albany Medical College.

Strateos is in the development of remote access laboratories and lab automation software for life science discovery.
Login
Username:

Password: